These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21659969)

  • 21. ALSUntangled #71: Nuedexta.
    Sun Y; Benatar M; Mascías Cadavid J; Ennist D; Wicks P; Staats K; Beauchamp M; Jhooty S; Pattee G; Brown A; Bertorini T; Barkhaus P; Bromberg M; Carter G; Bedlack R; Li X
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):218-222. PubMed ID: 37493197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
    Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
    Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of action of dextromethorphan/quinidine:comparison with ketamine.
    Stahl SM
    CNS Spectr; 2013 Oct; 18(5):225-7. PubMed ID: 24050154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.
    Allen C; Zarowitz B; O'Shea T; Peterson E; Yonan C; Waterman F
    Geriatr Nurs; 2018; 39(1):54-59. PubMed ID: 28807457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.
    Taylor CP; Traynelis SF; Siffert J; Pope LE; Matsumoto RR
    Pharmacol Ther; 2016 Aug; 164():170-82. PubMed ID: 27139517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
    Olney N; Rosen H
    IDrugs; 2010 Apr; 13(4):254-65. PubMed ID: 20373255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
    Haiman G; Pratt H; Miller A
    J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic options for emotional lability: current and emerging treatments.
    Weintraub D
    Am J Geriatr Pharmacother; 2005; 3 Suppl A():12-5; quiz 16-7. PubMed ID: 16305945
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review.
    Hicks AJ; Clay FJ; Ponsford JL; Perry LA; Jayaram M; Batty R; Hopwood M
    Neuropsychol Rev; 2020 Mar; 30(1):28-50. PubMed ID: 31942705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.
    Garcia-Baran D; Johnson TM; Wagner J; Shen J; Geers M
    Medicine (Baltimore); 2016 Mar; 95(12):e2886. PubMed ID: 27015166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review.
    Johnson B; Nichols S
    Palliat Support Care; 2015 Dec; 13(6):1797-801. PubMed ID: 24916672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of pseudobulbar affect including a novel and potential therapy.
    Schiffer R; Pope LE
    J Neuropsychiatry Clin Neurosci; 2005; 17(4):447-54. PubMed ID: 16387982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
    Smith R; Pioro E; Myers K; Sirdofsky M; Goslin K; Meekins G; Yu H; Wymer J; Cudkowicz M; Macklin EA; Schoenfeld D; Pattee G
    Neurotherapeutics; 2017 Jul; 14(3):762-772. PubMed ID: 28070747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.
    Young FG; Nguyen D
    J Med Case Rep; 2020 Dec; 14(1):235. PubMed ID: 33272325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRPS-related neurogenic edema responsive to dextromethorphan/quinidine.
    Ferrara JM
    Pain Med; 2014 Nov; 15(11):1981-3. PubMed ID: 25139080
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
    Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
    PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marketing and drug costs: who is laughing and crying?
    Johnston SC; Hauser SL
    Ann Neurol; 2007 Feb; 61(2):11A-12A. PubMed ID: 17315204
    [No Abstract]   [Full Text] [Related]  

  • 38. Dextromethorphan: From Cough Suppressant to Antidepressant.
    Kverno K
    J Psychosoc Nurs Ment Health Serv; 2022 Nov; 60(11):9-11. PubMed ID: 36317836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dextromethorphan and quinidine combination for heroin detoxification.
    Akerele E; Bisaga A; Sullivan MA; Garawi F; Comer SD; Thomas AA; Nunes EV; Kleber HD
    Am J Addict; 2008; 17(3):176-80. PubMed ID: 18463993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan.
    Drugs R D; 2005; 6(3):174-7. PubMed ID: 15869321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.